The National Association of State and Territorial AIDS Directors surveyed AIDS Drug Assistance Programs in September 1996. Risk factors are preexisting renal disease or recent exposure to aminoglycosides. Oral probenecid and intravenous prehydration with saline reduces nephrotoxicity. Agouron Pharmaceuticals Inc. has announced an expanded access program for nelfinavir, a new protease inhibitor. There was also a significant improvement in functional performance as measured by treadmill work output.
Side effects are infrequent and consist primarily of musculoskeletal discomfort.
The duration of treatment in trial was 12 weeks. The FDA is requiring a study of maintenance doses since this in-formation is not available. Cost is a concern, but the AWP has not yet been determined.